Expertise in
2
conditions

Marcelo H. Losso

B, AR 
Expertise in
2
conditions
B, AR 
OverviewLocationsClinical Research

Overview

Marcelo Losso practices in Argentina. Mr. Losso is highly rated in 2 conditions, according to our data. His top areas of expertise are HIV/AIDS, Severe Acute Respiratory Syndrome (SARS), Flu, and COVID-19.

His clinical research consists of co-authoring 72 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

B, Argentina
Other Locations
Ramos Mejia, B, Argentina
Buenos Aires, C, Argentina

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: October 21, 2024
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drugs: Infliximab, Abatacept, Remdesivir, Cenicriviroc
Study Phase: Phase 3
A Phase IIIB/IV Randomised Open-label Trial Comparing Dolutegravir With Pharmaco-enhanced Darunavir Versus Dolutegravir With Predetermined Nucleosides Versus Recommended Standard of Care ART Regimens in Patients With HIV-1 Infection Failing First Line Therapy.
A Phase IIIB/IV Randomised Open-label Trial Comparing Dolutegravir With Pharmaco-enhanced Darunavir Versus Dolutegravir With Predetermined Nucleosides Versus Recommended Standard of Care ART Regimens in Patients With HIV-1 Infection Failing First Line Therapy.
Enrollment Status: Unknown
Publish Date: April 18, 2023
Intervention Type: Drug
Study Drugs: NRTIs, Dolutegravir, Darunavir, Ritonavir
Study Phase: Phase 4
An International Observational Study of Outpatients With SARS-CoV-2 Infection
An International Observational Study of Outpatients With SARS-CoV-2 Infection
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Other
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
Enrollment Status: Completed
Publish Date: April 04, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Hyperimmune immunoglobulin to SARS-CoV-2, Remdesivir
Study Phase: Phase 3
COVID-19 in People Living With HIV: Evaluation of Risk Factors and Outcomes in Resource-limited Settings. A Pooled Substudy of ADVANCE, D²EFT, DolPHIN2 and NAMSAL
COVID-19 in People Living With HIV: Evaluation of Risk Factors and Outcomes in Resource-limited Settings. A Pooled Substudy of ADVANCE, D²EFT, DolPHIN2 and NAMSAL
Enrollment Status: Completed
Publish Date: March 18, 2022
Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria
Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria
Enrollment Status: Completed
Publish Date: September 30, 2020
Intervention Type: Other
Study Phase: Not Applicable
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: August 18, 2017
View 7 Less Clinical Trials

72 Total Publications

A randomised trial to compare dolutegravir plus boosted darunavir versus recommended standard of care antiretroviral regimens in people with HIV-1, whose first-line non-nucleoside reverse transcriptase inhibitor therapy has failed: Final 96-week results of the D2EFT study.
A randomised trial to compare dolutegravir plus boosted darunavir versus recommended standard of care antiretroviral regimens in people with HIV-1, whose first-line non-nucleoside reverse transcriptase inhibitor therapy has failed: Final 96-week results of the D2EFT study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: April 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Losso's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile